Showing 4641-4650 of 8849 results for "".
- Biopelle Launches Emepelle to Address Estrogen Deficient Skinhttps://practicaldermatology.com/news/biopelle-launches-emepelle-to-address-estrogen-deficient-skin/2459979/Biopelle, Inc. has launched Emepelle, the first and only clinically proven skincare line that safely and effectively helps address Estrogen Deficient Skin (EDS). Emepelle features MEP Technology, a patented, specifically designed ingredient that helps
- New Mouse Model Validates How “Good” and “Bad” Bacteria Affect Acnehttps://practicaldermatology.com/news/new-mouse-model-validates-how-good-and-bad-bacteria-affect-acne/2459981/Researchers at University of California San Diego School of Medicine, Cedars-Sinai and UCLA have developed a new mouse model that closely resembles human acne by adding one new factor — a synthetic sebum. Researchers have long believed that Propionibacterium acnes causes ac
- New HelloBello Baby Care Products Make a Big Splash at Walmarthttps://practicaldermatology.com/news/new-hellobello-baby-care-products-make-a-big-splash-at-walmart/2459983/Walmart is rolling out a host of new products from HelloBello, an affordable plant-based baby care line co-founded by Kristen Bell and Dax Shepard. Hello Bello will launch with 10 products including diapers, wipes, shampoo & body wash, bubb
- Get to Know the Dermatology Hall of Fame's 2019 Inaugural Class of Inducteeshttps://practicaldermatology.com/news/meet-the-dermatology-hall-of-fame-2019-inaugural-class-of-inductees/2459984/The 10 individuals inducted into the Dermatology Hall of Fame’s 2019 Inaugural Class are: Albert Bernard Ackerman, M.D., the author of “Histologic Diagnosis of Inflammatory Skin Diseases” and recipient of the American Academy of Dermatology’s Master Dermatologist
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Regenerative Medicine Breakthrough: Mobile Bedside Bioprinter May Heal Woundshttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-mobile-bedside-bioprinter-may-heal-wounds/2459876/Researchers have created a mobile skin bioprinting system that allows bi-layered skin to be printed directly into a wound. The team demonstrated proof-of-concept of the system by printing skin directly onto pre-clinical models, and the next step is to conduct a clinical trial in humans, t
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- Sentient Lasers Unveils Dot Demo Servicehttps://practicaldermatology.com/news/sentient-lasers-unveils-dot-demo-service/2459886/Sentient Lasers has launched its new,
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&